TT 816
Alternative Names: TT-816Latest Information Update: 19 Jul 2024
At a glance
- Originator Teon Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Cannabinoid receptor CB2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 31 May 2024 Pharmacodynamics data from preclinical studies in Solid tumours presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 07 Sep 2023 Teon Therapeutics terminates a Phase-I/II clinical trials in Solid tumours (Late-stage disease, Monotherapy, Combination therapy, Metastatic disease, Second-line therapy or greater) in USA due to safety and efficacy concern (PO) (NCT05525455)
- 20 Jan 2023 Teon Therapeutics enters into a clinical trial collaboration with Merck for phase I/II trial of TT 816 and pembrolizumab